NuCana PLC
NCNA0.660USD
0.000
Handelsschluss 04/24, 16:00（ET）Kurse um 15 Minuten verzögert
3.75MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über NuCana PLC Unternehmen
NuCana plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing treatment outcomes for patients with cancer by applying its ProTide technology. The Company's pipeline includes NUC-3373, and NUC-7738. NUC-3373 is a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil (5-FU). 5-FU is a prescribed anti-cancer agent. NUC-3373 has been evaluated in a Phase I clinical trial for patients with advanced solid tumors and is under Phase Ib/II clinical trial for patients with advanced colorectal cancer. NUC-7738 is a ProTide transformation of a nucleoside analog, 3’-deoxyadenosine (3’-Da). The Company is evaluating NUC-7738 in a Phase I/II clinical trial for patients with advanced solid tumors. Its pipeline also includes Acelari, which is a ProTide transformation of the nucleoside analog gemcitabine. The Company’s subsidiaries include NuCana, Inc., NuCana Limited and NuCana BioMed Trustee Company Limited.
Unternehmensinformationen
Unternehmens-codeNCNA
Name des UnternehmensNuCana PLC
IPO-datumSep 28, 2017
Gegründet am1997
CEOMr. Hugh S. Griffith
Anzahl der mitarbeiter20
WertpapierartDepository Receipt
GeschäftsjahresendeSep 28
AddresseLochside House
StadtEDINBURGH
BörseNASDAQ Capital Market Consolidated
LandUnited Kingdom
PostleitzahlEH12 9DT
Telefon4401313571111
Websitehttps://www.nucana.com/
Unternehmens-codeNCNA
IPO-datumSep 28, 2017
Gegründet am1997
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Hugh S. Griffith
Mr. Hugh S. Griffith
Chief Executive Officer, Co-Founder, Executive Director
Chief Executive Officer, Co-Founder, Executive Director
10.60K
--
Mr. Martin Mellish
Mr. Martin Mellish
Non-Executive Independent Director
Non-Executive Independent Director
1.33K
+18.87%
Dr. Elliott M. Levy, M.D.
Dr. Elliott M. Levy, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
749.00
+298.40%
Dr. Bali Muralidhar, M.D., Ph.D
Dr. Bali Muralidhar, M.D., Ph.D
Non-Executive Independent Director
Non-Executive Independent Director
22.00
--
Dr. Jeffrey D. Bloss, M.D.
Dr. Jeffrey D. Bloss, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Andrew Kay
Mr. Andrew Kay
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Dr. Cyrille Leperlier, M.D.
Dr. Cyrille Leperlier, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Christopher F. Brinzey
Mr. Christopher F. Brinzey
Investor Relations
Investor Relations
--
--
Dr. David Harrison, M.D.
Dr. David Harrison, M.D.
Head - Translational Studies
Head - Translational Studies
--
--
Mr. Donald (Don) Munoz
Mr. Donald (Don) Munoz
Chief Financial Officer
Chief Financial Officer
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Hugh S. Griffith
Mr. Hugh S. Griffith
Chief Executive Officer, Co-Founder, Executive Director
Chief Executive Officer, Co-Founder, Executive Director
10.60K
--
Mr. Martin Mellish
Mr. Martin Mellish
Non-Executive Independent Director
Non-Executive Independent Director
1.33K
+18.87%
Dr. Elliott M. Levy, M.D.
Dr. Elliott M. Levy, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
749.00
+298.40%
Dr. Bali Muralidhar, M.D., Ph.D
Dr. Bali Muralidhar, M.D., Ph.D
Non-Executive Independent Director
Non-Executive Independent Director
22.00
--
Dr. Jeffrey D. Bloss, M.D.
Dr. Jeffrey D. Bloss, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Andrew Kay
Mr. Andrew Kay
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionäre
Update-Zeit: Sat, Mar 22
Update-Zeit: Sat, Mar 22
Aktionärsstatistik
Art
Aktionärsstatistik
Aktionäre
Anteil
Sofinnova Investments, Inc
3.51%
Abingworth Management Limited
2.35%
Susquehanna International Group, LLP
0.82%
Schonfeld Strategic Advisors LLC
0.79%
Acadian Asset Management LLC
0.75%
Other
91.78%
Aktionärsstatistik
Aktionäre
Anteil
Sofinnova Investments, Inc
3.51%
Abingworth Management Limited
2.35%
Susquehanna International Group, LLP
0.82%
Schonfeld Strategic Advisors LLC
0.79%
Acadian Asset Management LLC
0.75%
Other
91.78%
Art
Aktionäre
Anteil
Venture Capital
5.86%
Investment Advisor
2.08%
Hedge Fund
1.60%
Research Firm
1.12%
Investment Advisor/Hedge Fund
0.78%
Individual Investor
0.22%
Other
88.33%
Institutionelle Beteiligung
Update-Zeit: Tue, Mar 4
Update-Zeit: Tue, Mar 4
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q1
50
678.81K
11.95%
+387.28K
2024Q4
52
469.91K
11.91%
+42.72K
2024Q3
52
279.81K
7.09%
-247.00K
2024Q2
51
362.89K
15.79%
-1.48K
2024Q1
59
340.51K
14.80%
-343.96K
2023Q4
65
549.25K
25.71%
-320.80K
2023Q3
68
668.24K
31.65%
-112.66K
2023Q2
71
571.34K
27.26%
-362.30K
2023Q1
81
667.89K
31.87%
-504.63K
2022Q4
87
672.60K
32.11%
-559.71K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Sofinnova Investments, Inc
199.52K
3.51%
+199.52K
--
Feb 14, 2025
Abingworth Management Limited
133.33K
2.35%
--
--
Dec 31, 2024
Susquehanna International Group, LLP
46.72K
0.82%
+46.72K
--
Dec 31, 2024
Schonfeld Strategic Advisors LLC
45.07K
0.79%
+45.07K
--
Dec 31, 2024
Acadian Asset Management LLC
42.41K
0.75%
+18.79K
+79.54%
Dec 31, 2024
Virtu Americas LLC
40.40K
0.71%
+40.40K
--
Dec 31, 2024
Baillie Gifford & Co.
36.70K
0.65%
--
--
Dec 31, 2024
Citadel Advisors LLC
25.00K
0.44%
+25.00K
--
Dec 31, 2024
Two Sigma Investments, LP
20.99K
0.37%
+20.99K
--
Dec 31, 2024
Glass Jacobson Wealth Advisors
15.00K
0.26%
--
--
Dec 31, 2024
Mehr Anzeigen
Verbundene ETFs
Name
Anteil
Keine Daten
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Apr 12, 2024
Merger
25<1
Apr 12, 2024
Merger
25<1
Apr 12, 2024
Merger
25<1
Apr 12, 2024
Merger
25<1
Datum
Art
Verhältnis
Apr 12, 2024
Merger
25<1
Apr 12, 2024
Merger
25<1
Apr 12, 2024
Merger
25<1
Apr 12, 2024
Merger
25<1